Search Results
Dec 08, 2025, 07:50 ET TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
cancer immunotherapy. Data demonstrating that the DOR is also expressed on T regs and controls the expression of FOXP3, a critical immunosuppressive gene, provides a shared mechanism by which endogenous opioids, via the DOR, control the immunosuppressive tone of both innate and adaptive immune responses
More news about: TuHURA Biosciences, Inc.
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
visual, gastrointestinal and sleep impairments as major features. It is caused by pathogenic variants in the Cyclin Dependent Kinase-like 5 (CDKL5) gene located on the X chromosome and affects four times more females than males. It is estimated that CDD affects approximately 1 in 40,000 to 60,000 live
More news about: UCB
Dec 08, 2025, 05:35 ET Exosomes Market Led by North America with 53% Revenue Share and Global Market Size Set to Surpass USD 2B by 2030, Says Mordor Intelligence
Therapeutics Therapeutic applications are gaining strong traction as researchers and biotech innovators engineer exosomes for targeted drug delivery, gene modulation, and regenerative therapies. Advancements in exosome engineering and scalable GMP-grade production are accelerating clinical-pipeline activity,
More news about: Mordor Intelligence Private Limited
Dec 08, 2025, 05:25 ET Voranigo® (vorasidenib) de Servier remporte le Prix Galien dans plusieurs pays
traitement des astrocytomes ou oligodendrogliomes de grade 2 ne prenant pas le contraste présentant une mutation R132 du gène IDH1 (isocitrate déshydrogénase-1) ou une mutation R172 du gène IDH2 (isocitrate déshydrogénase-2) chez les patients adultes et adolescents âgés de 12 ans et plus et pesant
More news about: Servier
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
visual, gastrointestinal and sleep impairments as major features. It is caused by pathogenic variants in the Cyclin Dependent Kinase-like 5 (CDKL5) gene located on the X chromosome and affects four times more females than males. It is estimated that CDD affects approximately 1 in 40,000 to 60,000 live
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
visual, gastrointestinal and sleep impairments as major features. It is caused by pathogenic variants in the Cyclin Dependent Kinase-like 5 (CDKL5) gene located on the X chromosome and affects four times more females than males. It is estimated that CDD affects approximately 1 in 40,000 to 60,000 live
More news about: UCB
Dec 07, 2025, 12:01 ET Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
bleed protection compared to prophylaxis treatment, and continued freedom from routine prophylaxis. HEMGENIX remains the only commercially available gene therapy for adults with hemophilia B and can be used in patients with or without AAV5 neutralizing antibodies.
More news about: CSL
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
(selpercatinib) is newly listed for the treatment of: 1) adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion, 2) adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who
More news about: Innovent Biologics
Dec 06, 2025, 15:40 ET Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
actionable gene fusions like NRG1.About BIZENGRI (zenocutuzumab-zbco)INDICATIONSBIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with
More news about: Partner Therapeutics, Inc.
Dec 06, 2025, 07:15 ET Studies Highlight Innovative Approaches to Improving Patient Care and Outcomes
common mutations seen in AML cells occurred at similar rates in Black and white patients. However, among patients with a mutation in one particular gene, known as NPM1, the analysis found a significant difference in overall survival, with Black patients surviving for a median of 8.9 months compared
More news about: American Society of Hematology
Dec 06, 2025, 07:00 ET Research Reveals Avenues for Informing and Improving Sickle Cell Care
studies examine gene therapies, which became available over the past few years as a curative option for both sickle cell disease and beta thalassemia, another disorder affecting red blood cells. The fourth study tracks the clinical practices and timelines involved in implementation of two gene therapies,
More news about: American Society of Hematology
Dec 05, 2025, 17:45 ET AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
tolerability, pharmacodynamic (PD) markers, and pharmacokinetics (PK) of AP-101 in patients with sporadic ALS and in patients with mutations in the SOD1 gene.About AL-S Pharma AGAL-S Pharma is a Swiss-based single-asset company founded and co-owned by Neurimmune and TVM Capital Life
More news about: AL-S Pharma AG
Dec 05, 2025, 13:14 ET Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications
particularly acute: recent research published by Blood Advances found that half of community oncologists and hematologists were not aware of recent gene therapy data for adult indications. Closing this gap requires credibility, clarity, and multiple pathways of engagement. "Clinicians are drowning
More news about: Decera Clinical
Dec 05, 2025, 08:00 ET Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
with age.3,4 Of patients newly diagnosed with AML and tested for FLT3 mutations, approximately one-third have an alteration to the FLT3 gene. FLT3-ITD mutations have been associated with worsened disease-free survival and overall survival, and a higher risk of getting the disease more than
More news about: Astellas Pharma Inc.
Dec 04, 2025, 16:54 ET Human Longevity Expands $1M Cancer Pledge to Redefine Early Detection and Prevention of Colon Cancer
shifting screening upstream toward true proactive prevention.Whole genome sequencing plays a critical role in identifying both inherited single-gene risk and complex polygenic risk for colon cancer, often years before symptoms or visible disease appear. When combined with imaging, biomarker analysis
More news about: Human Longevity, Inc.
Dec 04, 2025, 16:48 ET QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application ("BLA") submission. Specifically,
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 04, 2025, 15:45 ET Discovery could give investigators a new tool in death investigations
DeGennaro, a leading insect researcher, and Jeffrey Wells, whose insect research is tied to forensics, have identified a technique that focuses on a maggot's gene expression and metabolic changes to more accurately estimate how long someone has been dead. In doing so, they have created a molecular "clock" that
More news about: Florida International University
Dec 04, 2025, 15:17 ET AlidaBio Introduces the EpiPlex™ Duo-Mod™ Service for Concurrent m6A and Inosine Mapping with Integrated RNA Expression Profiling
protein analyses alone.The EpiPlex Duo-Mod Service applies AlidaBio's proximity barcoding and enrichment chemistry to profile m6A, inosine and gene expression from the same RNA input. This unified analysis enables researchers to identify genes with matched expression yet divergent modification states,
More news about: Alida Biosciences
Dec 04, 2025, 12:38 ET Q3 Ends With Decrease in Earnings Year-Over-Year, Increase in Functional Unemployment, Ludwig Institute Reports
@LISEP_org.About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder and CEO of Ludwig
More news about: Ludwig Institute for Shared Economic Prosperity
Dec 04, 2025, 10:01 ET Cleanroom Technologies Market Surges Toward US$10.58 Billion by 2031, Driven by Semiconductor Expansion and Biopharma Sterile Manufacturing
South Korea, Taiwan, and the EU expanded chip fabrication programs, while pharmaceutical companies scaled up sterile injectables, mRNA production, and gene therapy fill-finish operations.According to DataM Intelligence, consumables and equipment segments both expanded solidly, with growth
More news about: DataM Intelligence 4 Market Research LLP
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
#PS2-08-14Poster Session 2. December 10, 2025. 5:00 – 6:30 PM CSTTertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database. #PS2-09-08Poster Session 2.
More news about: Caris Life Sciences
Dec 04, 2025, 08:12 ET UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
3.051.21 Rodriguez N, et al. AAV Gene Therapy in Juvenile Mice of STXBP1 Haploinsufficiency. AES. 2025. Abstract number: 1.048.22 Rajman M, et al. Reactive Mouse Primary Astrocytes as a Model to Explore Glial Gene Expression Profiles Identified in Human Temporal Lobe
More news about: UCB
Dec 04, 2025, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Dec 03, 2025, 17:31 ET Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight
cases.Advancements in Gene TherapyGene therapy has emerged as a transformative approach in hemophilia A treatment. Notably, BioMarin's ROCTAVIAN has been approved in the U.S. and EU, offering a one-time infusion that provides long-term correction of the factor VIII deficiency. Pfizer's gene therapy
More news about: DelveInsight Business Research, LLP
Dec 03, 2025, 10:43 ET HIV Therapeutics Market to Reach USD 57.56 Billion by 2033 as Long-Acting Regimens, Integrase Inhibitors, and Next-Gen Combination Therapies Redefine Global HIV Care
resistant HIV strainsMulti-specific broadly neutralizing antibodies for combination therapyFunctional cure research through gene editing and immune modulationDigital adherence ecosystems integrated with ARTFurther expansion of low-cost generics in emerging
More news about: DataM Intelligence 4 Market Research LLP